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Abstract: This study was conducted with the aim of determining the effects of periodical hormonal fluctuations related to the menstrual
cycle on chromosome sensitivity and cytotoxicity. The study group consisted of 8 healthy donors (4 nonsmokers and 4 smokers).
Cytogenetic tests were done in vitro (in test tubes), and the known mutagenic effect of mitomycin C was added to determine chromosome
sensitivity. Blood was drawn from the donors at specified time intervals (follicular phase, ovulation phase, and luteal phase), and
control groups and mitomycin C-treated groups were formed. In the controls, the highest sister chromatid exchange frequency was
detected in the follicular phase and the lowest frequency was detected in the luteal phase of nonsmokers. In smokers, the highest sister
chromatid exchange frequency was detected in the ovulation phase and the lowest frequency was detected in the luteal phase. In terms
of chromosomal aberrations, the highest values were detected in the follicular phase and the lowest values were detected in the luteal
phase in nonsmokers. On the contrary, the highest rate of anomaly was detected in the luteal phase and the lowest rate of anomaly was
detected in the follicular phase in smokers. However, there was no statistically significant difference between these findings. The data of
the MMC application were similar in both groups. In this study, both the follicular phase and the ovulation phase showed slightly higher
chromosome sensitivity, while the chromosomes in the luteal phase were the most stable. These results are probably due to hormonal
fluctuation.
Key words: Menstrual cycles, endogenous sex hormones, chromosome sensitivity, sister chromatid exchange, chromosome aberrations

1. Introduction
Sex hormones (such as estradiol [E2], progesterone,
follicle stimulating hormone [FSH], and luteinizing
hormone [LH]) periodically fluctuate within certain
ranges in healthy adolescents and nonpregnant women
of reproductive age. The menstrual cycle is divided into 3
phases (follicular phase, ovulation phase, and luteal phase)
when this fluctuation is taken into consideration. Each
phase has unique natural endogenous hormone levels
and these hormonal fluctuations may easily be detected
in peripheral blood by using routine tests. Whether these
fluctuations have effects on chromosome sensitivity is
the main subject of this study. Despite the absence of
an exact consensus on the direct effect of hormones on
the chromosomes, all classes of hormones including the
steroid group are known to affect gene transcription,
either as a direct transcription factor or through activating
transcription factor (Nussey and Whitehead, 2001).
While androgens increase apoptosis, estrogens have
been determined to have a protective effect on cell death
* Correspondence: milenium@cu.edu.tr

(Cutolo et al., 2005). In other words, hormones show
epigenetic effects on the phenotype of the individuals
through changing gene transcription levels. It is not
clearly known whether alterations in gene transcription
have an effect on chromosome sensitivity or not. Before
analyzing the results of the studies on this topic, the effects
of exogenous risk factors like environmental pollutants or
exposure through diet on sex hormone levels, the main
subject of the study, must also be questioned. It is known
that gradually increasing the presence of environmental
pollutants including cigarette smoke and pesticides in
living areas leads to more exposure to them of all living
things, including humans. For example, some pesticides
produce clastogenic and aneugenic types of abnormalities,
and as a result, reduce the mitotic index (MI) in Allium cepa
root tip cells (Yüzbaşıoğlu et al., 2009). Smoking is one of
the main factors causing changes in reproductive hormone
levels in women (Thomford and Mattison, 1986; BarrettConnor and Khaw, 1987; Daniel et al., 1992; Sofuoglu et
al., 2001; Brand et al., 2011). Some pollutants show some
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direct or indirect effects (through biotransformation)
including estrogenic activities (Adami et al., 1995; Kojima
et al., 2005; Lee et al., 2012; Li et al., 2012). Strong evidence
and suspicions exist about the fact that exposure to
exogenous estrogen-like steroids (xenoestrogen) increases
different cancer types, mainly breast cancer (Stellman
et al., 1998; Meek and Finch, 1999; Rudel et al., 2001;
Charlier and Plomteux, 2002; Iwai et al., 2005; Meeks et al.,
2012). Because of 2 common properties of breast cancer,
estrogens were reported to increase genomic instability
through directly stimulating DNA mutation or aneuploidy
(Cavalieri and Rogan, 2002).
Estrogen is important for fertility and aids in regulating
the menstrual cycle during the fertile period. However,
lifelong estrogen exposure increases the risk for breast
(Sæther et al., 2012) and endometrial cancer (Jaakkola et
al., 2011) together. When genotoxic and cytotoxic effects
of xenoestrogen in the cells are analyzed, increased cell
proliferation rate was reported to bring the risks together.
These risks direct the cell to a neoplastic phenotype as
the accumulation of some genetic damage combinations.
These types of genetic errors and neoplastic transformation
were reported to be caused by hormones, drugs, infectious
agents, chemicals, physical or mechanic trauma, and
other chronic irritations (Preston-Martin et al., 1990).
An increased sister chromatid exchange (SCE) frequency
was observed in women who used ovulation-stimulating
drugs for in vitro fertilization (Joseph-Lerner et al., 1993).
Estrogens have been reported to induce tumors in organs
of rodents, except for the liver (Liehr, 1997). Adding
varying doses of 17β E2 to cultured human peripheral
blood lymphocytes significantly increased the SCE
number in the cell (Ahmad et al., 2000; Djelic and Djelic,
2002). In addition, E2 induced various genetic disorders
like some chromosomal and genetic lesions including
aneuploidy, chromosomal aberration, gene amplification,
and microsatellite instability under in vivo and in vitro
conditions with various cell test systems (Liehr, 2000).
The presence of indirect DNA damage related to estrogeninduced oxidation is already known, and estradiol and
synthetic estrogen have been found to induce quantitative,
structural chromosome aberrations and many types of
gene mutations in vivo. Estrogens including estradiol
and estrone are considered to be genotoxic carcinogens
(Cavalieri et al., 2000). In addition, micronucleus (MN)
formation arising from the chromosome-damaging effects
of estradiol has been suggested. It has been suggested
that induced genomic injury arises from suppression of
checkpoints responsible for hemostatic control of the
cell cycle (Fischer et al., 2001). In a similar study to ours
(Landi and Barale, 1999), significant fluctuations were seen
in SCE and chromosomal aberration (CA) frequencies
related with the menstrual cycle. In that study, while SCE
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frequency reached the maximum value at the end of the
menstrual cycle, it declined in ovulation, whereas CAs
tended to gradually increase beginning from menstruation
until the ovulation phase and gradually decreased
thereafter. MN values did not significantly fluctuate in
that study, and statistically significant differences in SCE,
CA, and MN frequencies were not observed. In human
peripheral lymphocytes obtained in certain phases of the
menstrual cycle and cultured in vitro, SCE frequencies
induced by mutagens were shown to be significantly
changed by endogenous sex hormones. These hormones
were reported to play a role in the suppression of cell
cycle checkpoints activated after any genetic errors in the
cells following mutagen treatment. This effect has been
suggested to be an epigenetic mechanism related with
hormone carcinogenesis (Cocchi et al., 2005). However, it
must be taken into consideration that drug-metabolizing
enzymes and polymorphisms in these enzyme receptors
are responsible for different reactions to the same effects
in cancer development in living organisms (Nebert et al.,
1999).
Knowing
potential
periodical
chromosomal
sensitivities or epigenetic mechanisms over a lifetime is
of great importance, in that we cannot exactly arrange the
optimal time to encounter these risks. Nevertheless, even a
partial arrangement of periods of drug use would provide
significant benefits in overcoming a periodic chromosomal
sensitivity process if present. We think that our work is
very important due to the above reasons.
2. Materials and methods
In this study, peripheral blood samples of reproductive-age
women obtained at 3 different times in the menstrual cycle
period (follicular, ovulation, and luteal phases) were used
as test material under in vitro conditions. To determine
sensitivity, mitomycin C (MMC; 0.25 µg/mL) was used for
24- or 48-h periods. In the study, CA and SCE tests were
used as short-term genotoxicity tests.
2.1. Method
Donors were a total of 8 healthy volunteer women, 4
nonsmokers (NS) and 4 smokers (S; have been smoking
11–20 cigarettes a day for 3–4 years) within the same
age range (23–28 years), with normal body mass index
(19–24.9 kg/m2), who have regular menstrual cycles, who
do not use oral contraceptives, and who do not have to
use any drugs due to any infectious or chronic diseases.
Blood was drawn 3 times from each woman, on day
4–6 of the menstrual cycle (follicular phase), day 14–15
(ovulation phase), and day 23–24 (luteal phase). Obtained
peripheral blood was subjected to hormone (FSH, LH,
E2, and progesterone) concentration detection in a center
accredited by the Joint Commission International (ÇÜTF
Balcalı Hospital, Central Laboratory); parallel samples
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obtained into heparinized tubes were incubated in
chromosome medium for use in the genotoxicity studies.

MI was also determined by scoring a total of 3000 cells
from each parameter.

2.2. Mitomycin C
MMC was used as a positive genotoxic agent in this study;
it is a strong DNA cross-linker. It achieves the cross link
through alkylating the molecule. This chemical is used as
an antitumoral agent today. The MMC (Kyowa, Hakko,
Japan; Sigma CAS No: 50-07-7) used in our study was
commercially provided.

2.4. Statistical significance
The normal distribution of the data was confirmed using
the nonparametric Kolmogorov–Smirnov test. Multiple
comparisons between the control and experimental groups
were performed using one-way ANOVA (Bonferroni test)
at P < 0.05. Chromatid and chromosome gaps were not
evaluated as chromosome aberrations (Mace et al., 1978).

2.3.. In vitro SCE and CA assays
The techniques by Evans (1984) and Perry and Thompson
(1984) were applied with minor modifications for
the preparation of chromosomes. This study was also
organized in agreement with the International Programme
on Chemical Safety guidelines (Albertini et al., 2000).
Eight voluntary healthy female donors were used in this
study. The blood samples (0.2 mL) taken from donors
were added to 2.5 mL of karyotyping medium (PB-MAX
[GIBCO], Cat. No. 12552-013) for the in vitro CA test, and
were supplemented with 10 µg/mL bromodeoxyuridine
(Sigma, B5002) for the in vitro SCE test. These cultures
were incubated at 37 °C for 72 h. The positive control
culture tubes were treated with MMC (0.25 µg/mL) for
24 or 48 h. Colchicine (0.06 µg/mL, Sigma C9754) was
added for the last 2 h of the cell culture in order to arrest
mitosis. The frequency of SCE was investigated by the
examination of 25 cells from each variable during the
second metaphase. These results were used to determine
the mean number of SCEs (SCEs/cell). Different types of
structural and numerical aberrations were investigated by
the examination of metaphases of 100 well-spread samples
for each donor. Furthermore, 100 cells from each donor, a
total of 800 cells, were scored for proliferation index (PI)
in nonsmoker and smoker donors. The PI was calculated
by the following formula: PI = [(1 × M1) + (2 × M2) + (3
× M3)] / total scored cells, where M1, M2, and M3 are the
fractions of cells undergoing the first, second, and third
mitosis, respectively, during the 72-h period of cell culture.

3. Results
3.1. Hormone levels of donors
Significant fluctuations were observed in the hormone
values of donors during the menstrual cycle. An overall
reduction was observed in the hormone values of smokers
except in a few cases. This reduction was found to be
significant, particularly in the ovulation phase (P < 0.05)
(Table 1).
3.2. Effect of menstrual cycle on SCE frequency
When data of the SCE test were analyzed, the highest SCE
concentration was detected in the follicular phase and the
lowest SCE frequency was found in the luteal phase in
untreated controls of NS donors. In the NS group, 48-h
MMC treatment significantly increased SCE frequency in
all 3 phases. Ovulation phase showed the maximum SCE
formation reaction to MMC (P < 0.01) (Table 2).
SCE frequencies in the S group were found to be
close to each other; however, insignificant variations
were detected. Similarly to the NS group, minimum SCE
frequency was detected in the luteal phase and maximum
frequency was detected in the ovulation phase. In this
group, 48-h MMC applications significantly increased SCE
frequency compared to the control (P < 0.01) (Table 2).
When SCE frequencies found in untreated controls
of smoking and nonsmoking donors were compared,
smoking did not indicate obvious SCE induction. No
significant difference occurred in other variables in terms
of smoking (Table 2).

Table 1. Mean hormone values of peripheral blood obtained from nonsmoking and smoking donors in different phases.
E2 (pg/mL)

FSH (mIU/mL)

LH (mIU/mL)

Prog. (ng/mL)

Phase

Nonsmokers

Smokers

Nonsmokers

Smokers

Nonsmokers

Smokers

Nonsmokers

Smokers

Follicular

38.00 ± 2.76

48.46 ± 8.55

5.93 ± 0.48

5.58 ± 0.64

7.47 ± 1.20

5.56 ± 0.48*

0.73 ± 0.22

0.64 ± 0.08

Ovulation

208.93 ± 105

71.94 ± 43.10*

8.01 ± 3.23

5.82 ± 0.53*

30.70 ± 18.20

16.72 ± 3.73*

1.32 ± 0.49

0.67 ± 0.09*

Luteal

113.14 ± 11.5

161.30 ± 37.20

2.69 ± 0.47

6.20 ± 1.46

6.20 ± 3.29

25.04 ± 13.3

4.97 ± 1.00

2.72 ± 2.04

Comparing the nonsmokers and smokers, *: P < 0.05.
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Table 2. SCE frequencies, abnormal cell percentage, and CA/cell ratio in peripheral blood obtained in various phases of the menstrual
cycle in nonsmokers and smokers.
Monthly
periods

Fol. phase

Ovu. phase

Lut. phase

Treatment

SCE/cell ± SE

CA/cell ± SE

Variables

Time
(h)

Nonsmokers

Smokers

Nonsmokers

Smokers

Nonsmokers

Smokers

Control

-

5.25 ± 0.40

5.21 ± 0.46

7.75 ± 0.47

6.50 ± 0.64

0.0875 ± 0.01

0.0775 ± 0.01

MMC

24

10.26 ± 1.07

12.29 ± 1.40 a1

11.00 ± 0.91 a1

9.75 ± 0.62

0.1375 ± 0.02

0.1200 ± 0.01

MMC

48

17.06 ± 2.06 a2

18.52 ± 2.46 a2

11.50 ± 0.64 a1

13.25 ± 1.03 a2

0.1225 ± 0.01

0.1675 ± 0.01 a2

Control

-

4.88 ± 0.26

5.41 ± 0.51

5.50 ± 0.28 b1

7.50 ± 0.50 d1

0.0625 ± 0.01

0.0925 ± 0.01 d2

MMC

24

8.79 ± 0.23

8.13 ± 1.04 b1

9.00 ± 0.91 a1

8.50 ± 0.86

0.1100 ± 0.01

0.0975 ± 0.01

MMC

48

21.68 ± 3.43 a2d1 16.59 ± 0.85 a3

10.00 ± 1.08 a1

17.50 ± 1.04 a3b1d2

0.1225 ± 0.01

0.2000 ± 0.01 a2d1

Control

-

4.32 ±0.26

4.95 ± 0.40

3.75 ± 0.47 b3

8.00 ± 0.40 d2

0.0375 ± 0.01 b2 0.9250 ± 0.01 d2

MMC

24

8.33 ± 0.83

7.76 ± 0.44 b1

7.75 ± 0.47 a2

8.75 ± 1.03

0.0825 ±0.01 a1

MMC

48

13.06 ± 2.25 a2

12.26 ± 1.05 a3

7.50 ± 0.64 a2b1

12.25 ± 0.85 a1c1d1

0.0775 ± 0.01 a1 0.1625 ± 0.01 a1d2

a: Compared with own control group.
a1b1c1d1:
b: Compared with analog in follicular phase. a2b2c2d2:
c: Compared with analog in ovulation phase. a3b3c3d3:
d: Compared with the non-smokers and smokers.

0.1100 ± 0.01

P < 0.05
P < 0.01
P < 0.001

3.3. Effect of menstrual cycle on chromosomal
abnormality
The most common chromosomal anomalies were found
to be chromatid (B’) and chromosome deletion (B’’) in
terms of chromosomal abnormalities of the various phases
of the menstrual cycle and chromosomal aberration per
cell. Although the high frequency of these 2 aberrations
suggests a clastogenic effect, no significant finding about
aneugenity was encountered.
For the nonsmoking group, significant CA frequency
was found in the follicular phase and the lowest CA was
found in the luteal phase (Table 2). These findings are
similar to those of SCE.
In the untreated controls of both the ovulation and
luteal phases in this group, CA frequencies were found to
be significantly higher than those of the NS group. These
results indicate that smoking increased CA formation.
Interestingly, individuals in the S group were observed to
have been affected more than those in the NS group during
the luteal phase (Table 2).
CA/cell frequency was found to be similar with CA
findings. Maximum frequency for this value was detected
also in the luteal phase (Table 2).
3.4. Cytotoxic effect
PIs of controls in the NS group were found to be similar in
all 3 phases. Although MMC treatment caused a reduction
in PI, it was not statistically significant (Table 3).
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When PI values obtained from donors of the S
group were analyzed in terms of untreated controls, the
maximum PI value was found in the follicular phase and
the minimum PI value was found in the ovulation phase.
MMC treatment led to significant effects in the follicular
phase only (Table 3).
When PI values in both the S and NS groups were
analyzed, smoking habit increased PI value except for a
few variables, and a significant difference was detected
between follicular phase controls (P < 0.05) (Table 3).
When MIs of the NS group were analyzed, the
minimum MI value was detected in the ovulation phase
and the maximum value was found in the luteal phase.
Significant differences were found between them (P <
0.05). MMC treatment reduces MI value severely (P <
0.01) (Table 3).
When MI values in controls in the S group were
analyzed, the maximum value was found in the follicular
phase and the minimum value was found in the luteal
phase. The MI value calculated in the follicular phase was
significantly higher than the MI value calculated in the
ovulation and luteal phases (P < 0.05), although MMC
treatment decreased MI values in this group significantly
(Table 3).
Smoking habit caused significant increase in MI values
in the follicular phase (Table 3).
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Table 3. Cytotoxic effects in peripheral blood obtained in various phases of the menstrual cycle in nonsmokers and smokers.

Monthly periods

Fol. phase

Ovu. phase

Lut. phase

Treatment

PI ± SE

MI ± SE

Variables

Time (h)

Nonsmokers

Smokers

Nonsmokers

Smokers

Control

-

1.80 ± 0.12

2.13 ± 0.08 d1

4.99 ± 0.02

5.08 ± 0.07

MMC

24

1.63 ± 0.05

1.74 ± 0.09 a1

4.22 ± 0.08 a3

4.64 ± 0.04 a2d2

MMC

48

1.57 ± 0.14

1.67 ± 0.09 a1

3.89 ± 0.05 a3

4.01 ± 0.02 a3d1

Control

-

1.84 ± 0.09

1.86 ± 0.07

4.66 ± 0.08 b1

4.76 ± 0.06 b1

MMC

24

1.70 ± 0.03

1.60 ± 0.14

4.18 ± 0.04 a2

4.38 ± 0.11 a1b1

MMC

48

1.69 ± 0.11

1.47 ± 0.07

3.87 ± 0.06 a3

3.97 ± 0.07 a3

Control

-

1.77 ± 0.13

1.90 ± 0.10

5.02 ± 0.07 c1

4.95 ± 0.03 b1

MMC

24

1.62 ± 0.11

1.67 ± 0.14

4.32 ± 0.15 a2

4.10 ± 0.05 a3b2

MMC

48

1.63 ± 0.06

1.65 ± 0.02

3.85 ± 0.08 a3

3.89 ± 0.03 a3

a: Compared with own control group.
a1b1c1d1:
b: Compared with analog in follicular phase.
a2b2c2d2:
c: Compared with analog in ovulation phase.
a3b3c3d3:
d: Compared with the non-smokers and smokers.

4. Discussion
Potential genotoxicity findings related to the menstrual
cycle must be taken into consideration along with exposure
to environmental risk factors in life. Data on which phase
(follicular, ovulation, and luteal phases) carries more risk
for chromosome sensitivity or which phase is more stable
are of great importance for the health of the individual, and
these data may be evaluated in the context of preventive
health. The menstrual cycle, a physiologic event for
reproductive-age women, is a process repeated every 28
days until menopause except during periods of pregnancy.
Significant hormonal fluctuations occur in endogenous
sex hormones (E2, FSH, LH, and progesterone). These
fluctuations are known to cause some genetic and/or
epigenetic effects in cells (Fowden and Forhead, 2009).
Hormones have been detected to be a direct transcription
factor (Nussey and Whitehead, 2001) and have been
shown to have a protective effect against cell death (Cutolo
et al., 2005). In addition, estrogen was reported to increase
genomic imbalance through directly stimulating DNA
mutation or aneuploidy, and this also increases breast
cancer risk related with initiation of oxidative damage
(Cavalieri and Rogan, 2002). In a similar study (Landi
and Barale, 1999), significant fluctuations were observed
in SCE and CA related with the menstrual cycle. In that
study, while SCE reached its maximum value at the end
of the menstrual cycle, it declined during ovulation,
whereas CA tended to gradually increase beginning from
menstruation to the ovulation phase and it decreased
gradually thereafter. In the same study, MN did not

P < 0.05
P < 0.01
P < 0.001

significantly fluctuate. In that study, it was emphasized
that changes occurred in genotoxicity findings related with
endogenous sex hormone fluctuations, and significant
fluctuations were also detected in our study. However,
while these results are consistent with those of our study
in some aspects, they are also inconsistent with some parts
of our study. In our study, the severity of cellular reaction
to MMC treatment was found to be as important as the
untreated control findings, because these results enable us
to estimate the outcomes of exposure to environmental
risk factors at any stage of the menstrual cycle. We want to
draw attention to hormone level increases in the ovulation
phase in the NS group and in the luteal phase in the S
group before analyzing the results of the tests applied as
the indicator of mutagenity.
The proliferative effect of smoking that we consider to
arise from suppressing checkpoints of the cell cycle was
particularly observed in the follicular phase, and this effect
indicates the tumorigenic and carcinogenic properties of
smoking. In summary, it was put forward that the most
sensitive phases in terms of SCE and CA response to MMC
treatment were the follicular and ovulation phases—the
first half of the menstrual cycle—and the most stable
phase was the luteal phase. We consider that the results
of our study should be supported with other studies and
additional test systems.
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